MeiraGTx Holdings plc (MGTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$73.8M
Cash & Equivalents
$17.8M
Quarterly Burn Rate
$1,240M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05060341 | Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia | OTHER | Active Not Recruiting | 22 |
| NCT05894343 | Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease | PHASE2 | Active Not Recruiting | 13 |
| NCT05926765 | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | PHASE2 | Recruiting | 276 |
| NCT06544798 | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | PHASE2 | Enrolling By Invitation | 276 |
| NCT02446249 | Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parot... | PHASE1 | Active Not Recruiting | 17 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-07 | 8-K | MeiraGTx Holdings plc (MGTX) (CIK 0001735438) - EX-10.1 | EDGAR |